Ocular Hypertension — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for ocular hypertension. 59 active patents protecting 5 drugs from 3+ originators. First major cliff: 2029. Daily refresh.

5
Approved drugs
59
Active US patents
63/100
Avg vulnerability
—
Annual revenue covered

Originators in Ocular Hypertension

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Thea Pharma 20 patents Senju Pharmaceutical Co., Ltd 18 patents Bausch Health 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating ocular hypertension. Each bar = one year. Y-axis scaled to peak year (15 patents).

7
26
4
27
1
28
11
29
15
30
10
31
9
34
1
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Xalatan
LATANOPROST
 Thea Pharma 20 65 — 2026-07-11
Alphagan
BRIMONIDINE TARTRATE
 Senju Pharmaceutical Co., Ltd 18 69 — 2029-07-27
Travatan
TRAVOPROST
 — 11 54 — 2027-09-20
Lumigan
BIMATOPROST
 — 9 52 — 2026-12-19
Vyzulta
LATANOPROSTENE BUNOD
 Bausch Health 1 75 — 2029-02-21

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11596600 Alphagan method of use 81 2029-07-27
8455494 Alphagan method of use 81 2030-05-24
12201557 Travatan method of use 81 2030-06-18
8293742 Alphagan method of use 81 2030-07-14
9259425 Alphagan method of use 81 2030-07-14
8637054 Xalatan method of use 81 2031-07-08
8450344 Xalatan method of use 80 2026-07-11
11021456 Xalatan method of use 80 2026-07-11
10882840 Xalatan method of use 80 2026-07-11
9096569 Xalatan method of use 80 2026-07-11

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9415043 Xalatan composition of matter 4 2034-03-14
8629185 Lumigan composition of matter 10 2031-07-15
7851504 Lumigan composition of matter 22 2027-06-13
12201555 Travatan composition of matter 23 2031-02-14
9492316 Lumigan formulation 42 2034-10-31
11197853 Xalatan formulation 42 2034-03-14
11185538 Xalatan formulation 42 2034-03-14
10201517 Alphagan formulation 48 2031-06-13
9044484 Alphagan formulation 48 2030-10-30
9421265 Alphagan formulation 48 2030-06-17

Related